Something remarkable is happening in Chinese biotech, and it’s happening fast. The country’s drug developers are learning to run — really run — through clinical trials and regulatory approvals. In an industry famous for glacial timelines and billion-dollar budgets, China’s pace feels almost alien.
Chinese companies are developing drugs faster and cheaper than anyone else, including the U.S. And while the early focus has been on copycat drugs and incremental improvements, it’s possible that something more profound might emerge from that ecosystem: a new productive way of developing drugs.
For decades, the biotech industry has been trained to think of drug discovery as a process of target-based design: find a biological target, hit it with a molecule, test it, refine it, repeat. The whole edifice of modern pharma is built on that logic.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
